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Vaginal type-II mucosa is an inductive site for
primary CD8þ T-cell mucosal immunity
Yichuan Wang1, Yongjun Sui1, Shingo Kato1, Alison E. Hogg1,2, Jason C. Steel3,4,
John C. Morris5 & Jay A. Berzofsky1
The structured lymphoid tissues are considered the only inductive sites where primary T-cell
immune responses occur. The naı¨ve Tcells in structured lymphoid tissues, once being primed
by antigen-bearing dendritic cells, differentiate into memory T cells and trafﬁc back to the
mucosal sites through the bloodstream. Contrary to this belief, here we show that the vaginal
type-II mucosa itself, despite the lack of structured lymphoid tissues, can act as an inductive
site during primary CD8þ T-cell immune responses. We provide evidence that the vaginal
mucosa supports both the local immune priming of naı¨ve CD8þ T cells and the local
expansion of antigen-speciﬁc CD8þ T cells, thereby demonstrating a different paradigm for
primary mucosal T-cell immune induction.
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L
ying at the interface between host and environment, the
mucosal tissue acts as the port of entry for multiple
pathogens. During viral transmission through mucosal
tissues, the presence of local antigen (Ag)-speciﬁc immune cells
is considered to help control infections by multiple viruses, such
as inﬂuenza virus (Flu)1–3, human immunodeﬁciency virus
(HIV)4–8, Simian immunodeﬁciency virus (SIV)9–11 and herpes
simplex virus (HSV)12–15. Although the mucosal local Ag-speciﬁc
T cells play an important role to protect against viral
transmission, the mechanisms through which the local Ag-
speciﬁc T-cell immunity can be generated in mucosal tissues,
especially in type-II mucosa (found in vagina, glans penis and
oesophagus)16–19, remain to be elucidated.
It is widely believed that primary immune T-cell induction in
type-II mucosa occurs only in the draining lymph nodes (DLNs)
but not in the mucosa itself due to a lack of mucosa-associated
lymphoid tissue (MALT) or secondary lymphoid tissues16–19. In
this process, the naı¨ve T cells in DLNs are primed by the Ag-
bearing dendritic cells (DCs) migrating from the Ag-exposed
mucosa and differentiate into memory T cells that are then able to
trafﬁc back to mucosal sites through the bloodstream20–23. It has
been shown that local secondary immune responses can protect
against viral infection24–26, and that protective vaginal immunity
can occur in lymph node-deﬁcient mice13, as well as that
lymphoid clusters can form in virus-infected vaginal mucosa15.
However, whether a primary immune response can be induced
locally in the type-II mucosal tissues without help from any
distant tissue or lymphoid site remains a fundamental question to
be answered.
In the current study, we develop a unique dual-transfer model,
by which we clearly demonstrate that adoptively transferred naı¨ve
OT-I CD8þ T cells are activated in the vaginal mucosa but not in
the DLNs 24 h after intravaginally (Ivag) immunization under
conditions where cells from the circulation or DLNs cannot reach
the vaginal mucosa. Even without adoptive transfer, Ag-speciﬁc
CD8þ T-cell activation is found to occur locally in the vaginal
mucosa after vaginal immunization before it occurs in DLNs. In
addition, the immunized vaginal tissue can induce naı¨ve OT-I
CD8þ T-cell activation that is largely dependent on local
antigen-presenting cells (APCs). Finally, vaginal mucosa also
supports the local expansion of Ag-speciﬁc CD8þ T cells. In
conclusion, we present an evidence of a new paradigm for
primary CD8þ T-cell immune induction in type-II mucosa of the
vagina, one that occurs locally without the help of draining LNs,
MALT or any other tissue site of priming, thereby providing a
new rationale for local mucosal immunization.
Results
DLN-independent priming of CD8þ T cells in vaginal mucosa.
Our study started with our observation that Ivag-immunized LN-
deﬁcient lymphotoxin-alpha-knockout (LTa KO) mice27,28 could
still be immunized Ivag despite lack of DLNs. To test the necessity
of DLNs for vaginal CD8þ T-cell immune induction, we used a
replication-deﬁcient adenovirus-5-expressing the hen ovalbumin
immunodominant Kb-restricted SIINFEKL peptide (rAd5-
SIINFEKL) to Ivag immunize the LN-deﬁcient lymphotoxin-
alpha-knockout (LTa KO) mice27,28 (Fig. 1a) and measured the
vaginal SIINFEKL-speciﬁc CD8þ T cells 14 days post
immunization (PI). Signiﬁcantly elevated levels of SIINFEKL-
speciﬁc CD8þ T cells could be detected in the vaginal mucosa of
LTa KO mice (Fig. 1b,c), although the percentage was lower than
that in wild-type (WT) animals. To understand the vaginal T-cell
distribution after Ivag immunization, we examined the vaginal
tissue sections and found that immunization-induced CD3þ cell
clusters formed in both WT and LTa KO mice (Fig. 1d). To
further identify the phenotype of cluster-forming cells, we stained
CD8 and CD11c on the consecutively cut tissue sections right
next to each other. The adjacent tissue section staining showed
that the CD3þ cell clusters in the immunized mice also
contained CD8þ and CD11cþ cells (Fig. 1d). In contrast to
the immunized mice, the vaginal CD3þ cells in naı¨ve animals did
not form clusters, but rather they were present sporadically as
isolated cells in lamina propria (LP) and epithelium (Fig. 1d).
These results clearly demonstrated that primary Ivag
immunization could induce the LN-independent Ag-speciﬁc
CD8þ T-cell immune response associated with the immune
cell aggregation, that is, the formation of inducible vaginal
lymphoid tissue (IVALT). Although the IVALT-associated Ag-
speciﬁc CD8þ T-cell response can be induced in the vaginal
mucosa independent of LNs, consistent with the recent ﬁndings
on protective immunity of Roth et al.13, we still do not know
whether these Ag-speciﬁc CD8þ T cells are derived from the
primed local naı¨ve T cells in the vaginal mucosa or they migrate
from other non-lymphoid tissue compartments, such as the
liver29–31. To test whether or not the vaginal mucosa itself could
act as an inductive site for the primary CD8þ T-cell immune
responses, we wanted to determine whether a primary CD8þ
T-cell response could be generated locally in the vaginal mucosa
of WT mice.
The availability of naı¨ve CD8þ T cells in vaginal mucosa.
Because the availability of naı¨ve T cells is a prerequisite for the
generation of primary T-cell immune responses, we ﬁrst assessed
whether naı¨ve CD8þ T cells were present in the vaginal mucosa.
To ensure the CD8þ T cells we identiﬁed from the digested
vaginal tissue were the interstitial cells, we intravenously (i.v.)
injected ﬂuorochrome-labelled Thy1.2 antibody at a dose of 25 ng
per mouse that could stain all the T cells in the blood collected
from retro-orbital plexus within 1min (Supplementary Fig. 1a),
which means that all the vasculature T cells can be stained by this
method. Using the intravascular T-cell staining32, we can clearly
distinguish the interstitial T cells from the blood T cells, although
some of the tissue-residing cells might be stained by the antibody
that leaks out from the capillaries, so the unstained cells represent
a lower limit on the number of tissue-residing cells. In digested
vaginal tissues, we found that around 86% (median¼ 86.7%)
of naı¨ve CD8þ T cells (CD62Lhigh/CD44low) were present
extravascularly, that is, in the vaginal mucosal parenchyma, but
not in associated vasculature (Supplementary Fig. 1a,b).
We then examined the phenotype of vaginal CD8þ T cells
from mice treated either with or without FTY720, a sphingosine-
1-phosphate receptor agonist, which inhibits lymphocyte egress
from both thymus and lymph nodes33 (Fig. 2). In FTY720-
untreated mice, 44% (44.7%±4.1%; mean±s.e.m.) of vaginal
CD8þ T cells showed a naı¨ve phenotype characterized as
CD62Lþ , CD44low and lacking CD25 and CD69 expression
(Fig. 2b,c). Four days after FTY720 treatment, the naı¨ve CD8þ
T-cell population in the vaginal mucosa was lost (Fig. 2b,c).
To determine the location of CD8þ T cells in vaginal mucosa,
we assayed the number of vaginal CD8bþ cells in the mice either
with or without FTY720 treatment by immunohistochemistry
(IHC; Fig. 2d,e). In FTY720-treated animals, the ratio of LP
CD8bþ cells/intraepithelial (IEP) CD8bþ cells signiﬁcantly
decreased (Po0.0001 by a Student’s t-test) from 2.03±0.097
(mean±s.e.m.) to 0.53±0.059 (Fig. 2d,e). Although it is difﬁcult
to count and compare the absolute number of total CD8þ T cell
in both LP and IEP due to the sporadic cell distribution, the lower
LP/IEP ratio in FTY720-treated animals is highly suggestive of
FTY720-induced vaginal naı¨ve T-cell depletion occurring to a
greater extent in the LP. Even though naı¨ve lymphocytes are
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known to preferentially recirculate among the secondary
lymphoid organs34,35, there is an increasing evidence showing
that CD8þ recent thymic emigrants migrate directly into the
small intestine and that naı¨ve T and B lymphocytes are present in
multiple peripheral tissue compartments36–39. Therefore, our data
demonstrated that naı¨ve CD8þ T cells routinely migrated into
the vaginal mucosal LP and the maintenance of this population
depended on the lymphocyte recirculation or replenishment from
the bloodstream.
Naı¨ve T-cell vaginal mucosal priming 24 h post Ivag vaccine.
To determine whether the naı¨ve CD8þ T cells could be primed
locally in the vaginal mucosa of WT mice, independent of DLNs,
we developed a dual-transfer model (Fig. 3a). We isolated CD8þ
T cells from Rag1 KO, OT-I transgenic C57BL/6 mice that solely
express a T-cell receptor (TCR) recognizing the ovalbumin pep-
tide SIINFEKL-H-2Kb complex. We depleted CD44high cells from
the OT-I CD8þ T cells to enrich the naı¨ve population (CD44low
and CD62Lþ ) to 98.5% (Fig. 3a). Identical aliquots of the naı¨ve
OT-I CD8þ T cells were labelled with either carboxyﬂuorescein
succinimidyl ester (CFSE; green) or violet dye and adoptively
transferred either Ivag or i.v., respectively, into the same recipient
mouse that had been Ivag immunized either 8 h (Fig. 3b) or 32 h
(Fig. 4a) earlier with SIINFEKL peptide plus DOTAP, a cationic
liposome facilitating major histocompatibility complex-I-restric-
ted Ag presentation, and mutant labile toxin (mLT), a mucosal
adjuvant. To further block lymphocyte recirculation, we also gave
each mouse FTY720 at 24 h before euthanasia, which decreased
the number of blood CD8þ T cells to background levels from
8–24 h post treatment (Fig. 3a).
To validate the reliability of our dual-transfer system, we tested
the effectiveness of T-cell recirculation blockage mediated by
FTY720 treatment. WT mice received FTY720 IP injection
followed by i.v.-transferred, CFSE-labelled naı¨ve CD8þ T cells
(5 106 per mouse) at 8 h after FTY720 treatment. Sixteen hours
after adoptive transfer, we collected and combined ﬁve vaginal
tissues from the mice that had received either naı¨ve CD8þ T cells
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Figure 1 | Vaginal Ag-speciﬁc CD8þ T-cell immune responses in LTa KO LN-deﬁcient mice. (a–c) The percentage of SIINFEKL-speciﬁc CD8þ Tcells in
the vaginal mucosa of both LTa KO, LN-deﬁcient mice and WTmice. This is representative of two independently repeated experiments (n¼ 3 per naı¨ve
control group; n¼4 per immunized group) with the same results. (a) Experimental design. (b) The gating strategy. (c) The percentage (mean±s.e.m.) of
SIINFEKL-speciﬁc vaginal CD8þ T cells in each group. The P value was generated using Student’s t-test. (d) Representative IHC staining showing the
formation of immune cell clusters containing CD3þ , CD8þ and CD11cþ cells in the immunized WT and LTaKO mice. Scale bar: 100mm in 40
photomicrographs; 400mm in  10 photomicrographs. Imm, immunized.
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or naı¨ve CD8þ T cells plus FTY720 or PBS. The transferred naı¨ve
CD8þ T cells were examined using ﬂow cytometry and no
CFSEþ events were noted in the vaginal tissues from the
FTY720-treated mice, whereas they were clearly detected in the
absence of FTY720. This is direct evidence that FTY720
completely blocked the naı¨ve CD8þ T-cell vaginal inﬁltration
from the blood stream (Supplementary Fig. 2).
We investigated the vaginal CD8þ T-cell immune priming at
24 h PI (16 h after dual transfer; Fig. 3b). In the vaginal mucosa,
the only detectable transferred population was the green CFSE-
labelled cell population injected directly into the vaginal mucosa
(Fig. 3c). The percentage of green CFSE-labelled OT-I CD8þ
T cells out of total vaginal CD8þ T cells was about 50%
(51.2%±4.9%; mean±s.e.m.), which means the number of
transferred naı¨ve CD8þ T cells within the vaginal tissue was
similar to that of the endogenous CD8þ T cells (that is,
physiological levels; Fig. 3c). The CD69 expression of Ivag-
transferred cells was signiﬁcantly higher in the Ivag-immunized
mice (84%±2.9%; mean±s.e.m.) than the naı¨ve control animals
(10.9%±2.7%; mean±s.e.m.; Po0.0001 by a Student’s t-test;
Fig. 3c,e), indicating that these cells were primed by the Ivag
immunization. Since the violet-labelled i.v.-transferred cells were
not detectable in the vaginal mucosa 24 h after immunization
(Fig. 3c), there were no transferred T cells entering the vaginal
mucosa through the bloodstream in the presence of FTY720.
Therefore, the green CD69þ Ivag-transferred cells would not yet
have been able to trafﬁc back to vaginal mucosa from the DLNs
(or any other tissue) where they could potentially have been
activated. Thus, the CD69þ green Ivag-transferred cells in the
vaginal mucosa had to be primed locally. For comparison, the
draining iliac LN contained both i.v.-transferred and Ivag-
transferred cells (Fig. 3d). The i.v.-transferred cells showed
similar low levels of CD69 expression in the immunized as in the
naı¨ve animals, indicating a lack of priming in the DLN by the
Ivag immunization at 24 h. In contrast, the CD69 expression of
the green Ivag-transferred cells was signiﬁcantly higher in the
immunized mice than unimmunized mice. Since the violet-
labelled i.v.-transferred cells had not been activated in the iliac LN
by 24 h PI, those green CD69þ Ivag-transferred cells in iliac LNs
would not have been activated in the LNs, but should be the ones
activated in the vaginal mucosa that then migrated into the DLNs.
For further conﬁrmation, we also performed a similar dual-
transfer study in LN-deﬁcient lymphotoxin-alpha-knockout (LTa
KO) mice27,28 (Fig. 3f–h). Similar to what was observed in WT
mice, the green Ivag-transferred cells within the vaginal mucosa
were activated at 24 h PI without any evidence of any T-cell
vaginal homing through the bloodstream (violet i.v.-transferred
cells; Fig. 3f,h). Because the LTa KO mice don’t develop
any LNs, we checked the liver that also possesses multiple
immune functions29. Similar to what has been shown by other
groups30,31, the immune priming, characterized by the expression
of CD69 on i.v.-transferred violet cells, was detected in the liver
that contained only the i.v.-transferred violet cells, but not the
Ivag-transferred green cells (Fig. 3g,h). Even though the naı¨ve
CD8þ T cells were able to be activated in the liver, none of the
liver-primed (violet) CD8þ T cells could enter the vaginal
mucosa (Fig. 3f,h). Direct priming in the vaginal mucosa was
further conﬁrmed in a second LN-deﬁcient mouse model, CXCR5
KO mice40, in which the Ivag-transferred green cells could be
primed locally in vaginal mucosa, while no violet cells from the
blood had entered the mucosa (Supplementary Fig. 3). Thus, the
data from both WT and LN-deﬁcient mice clearly demonstrated
that the Ivag-transferred naı¨ve CD8þ T cells could be primed
locally in this type-II mucosa, without any signs of LN immune
priming and/or the trafﬁcking of CD8þ T cells through the blood
from any other tissue site to the vaginal mucosa. Therefore, we
conclude that the naı¨ve CD8þ T cells could be primed locally in
the vaginal mucosa independent of LNs, contrary to the well-
accepted paradigm.
Naı¨ve T-cell vaginal mucosal priming 48 h post Ivag vaccine.
To characterize the kinetics of immune priming in vaginal
mucosa and in draining LNs, we extended our observations to
48 h PI (Fig. 4a). In the vaginal mucosa, still containing no violet
i.v.-transferred cells, the green Ivag-transferred cells still remained
activated, although at a lower level than observed at 24 h PI
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Figure 2 | The phenotype and distribution of CD8þ T cells in vaginal
mucosa of WT mice with or without FTY720 treatment. (a–c) The naı¨ve
CD8þ T cells in the vaginal mucosa of WT mice with depo-provera-
synchronized oestrous cycle. This is representative of three independently
repeated experiments (n¼ 5) with the same results. (a) Experimental
design. (b) The gating strategy to identify vaginal naı¨ve CD8þ T cells.
(c) The percentage (mean±s.e.m.) of naı¨ve CD8þ T cells in vaginal
mucosa with or without FTY720 treatment. (d,e) Representative results of
vaginal IHC staining showing the distribution of C8bþ cells in vaginal LP
and epithelium. (d) Representative IHC photomicrographs showing the
CD8 bþ cell in both vaginal epithelium and LP of the mice treated either
with or without FTY720 (Scale bar, 400 mm). (e) The ratio of LP C8bþ
cells/IEP C8bþ cells summarized from the pool of three independently
repeated experiments (n¼ 15). The numbers of LP and IEP C8bþ cells were
counted from three vaginal tissue sections from each animal. To avoid
counting the same cell multiple times on adjacent tissue sections, we
selected the slides with the vaginal tissue sections that were cut 25 mm
apart based on the diameter of T cells (5–20mm) (ref. 63). The P value was
generated using a Student’s t-test.
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(Fig. 4b,d). In the iliac LN, the violet i.v.-transferred cells started
being activated by 48 h, as assessed by the high level of CD69 in
the immunized compared with unimmunized mice (Fig. 4c,d).
The ability to detect priming of violet i.v.-transferred cells in the
DLN at 48 h may be due to the migration of vaginal Ag-bearing
DCs to the draining LNs by 48 h. Therefore, the Ag-speciﬁc
immune activation of naive CD8þ T cells could take place in
both vaginal mucosa and DLNs at 48 h PI, but also at this time
point, priming in the DLN could not account for primed T cells
in the vaginal mucosa in the presence of FTY720, as no
i.v.-transferred cells were yet able to enter the vaginal mucosa
(Fig. 4b).
Naı¨ve vaginal T-cell priming under physiological conditions.
The dual-transfer study clearly demonstrated that the immune
priming of naı¨ve vaginal CD8þ T cells could be a completely
local process (Figs 3 and 4). We further conﬁrmed whether local
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immune priming could occur in completely intact vaginal mucosa
without adoptive transfer of the T cells. We studied the Ag-spe-
ciﬁc immune activation of vaginal CD8þ T cells in Ivag-immu-
nized Rag-I KO, OT-I transgenic mice (Fig. 5). At 8 h after
immunization, the CD69 expression of CD8þ T cells could be
detected only in vaginal mucosa but not in DLNs (iliac LNs)
(Fig. 5a,b) or in any other tissue compartments including axillary
LNs, inguinal LNs, spleen and lung (Supplementary Fig. 4). Thus,
the CD69-expressing CD8þ T cells detected at 8 h after immu-
nization provided supportive evidence that immune priming is
likely to be a local process occurring in the vaginal mucosa but
not in the DLNs. In contrast, only at 12 h after immunization,
priming was starting to occur in the DLNs (Fig. 5a,b). Thus, the
kinetics support our conclusion from the dual-transfer studies
(Figs 3 and 4) that priming can occur directly in the vaginal
mucosa without requiring migration of cells primed in the DLN.
Also, we see again that priming in the DLN occurs later than in
the mucosa. To further conﬁrm that the CD69-expressing CD8þ
T cells originated from the phenotypically naı¨ve cells (CD62Lþ
and CD44low population) that were the majority (86.5%±2.4%;
mean±s.e.m.) of total vaginal CD8þ T cells in unimmunized
OT-I mice (Fig. 5c, left plots and Fig. 5d), we checked the CD62L
and CD44 expression on the CD69-expressing CD8þ T cells in
the vaginal mucosa of both naı¨ve and immunized animals (Fig. 5c
right plots and Fig. 5e). In the immunized animals at 8 h PI, the
percentage of naı¨ve cells among total vaginal CD8þ T cells
dropped down to 62.1%±1.2% (mean±s.e.m.), which was
signiﬁcantly lower (P¼ 0.0009 by a Student’s t-test) than that of
unimmunized animals (Fig. 5c, left plots and Fig. 5d). More
importantly, among the subset that expressed the CD69 activa-
tion marker, the percentage of CD44low and CD62Lþ cells out of
the total CD69-expressing CD8þ T cells was 50.6%±1.4%
(mean±s.e.m.), which was signiﬁcantly higher (P¼ 0.0012 by a
Student’s t-test) than that of naı¨ve animals (5.3%±5.3%;
mean±s.e.m.; Fig. 5c right plots and Fig. 5e). Therefore, the
CD69 was expressed mostly by the vaginal CD8þ T cells with the
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naı¨ve phenotype (CD62Lþ and CD44low) that had not yet
downregulated CD62L or upregulated CD44 at 8 h after immu-
nization, but not CD8þ T cells with the memory phenotype
(CD62L and CD44high). This shows that the primed cells are
derived from the naı¨ve population and not the tiny fraction of
memory cells in the unimmunized mucosa. Taken together, this
experiment conﬁrmed that the local immune priming can occur
on the naı¨ve endogenous CD8þ T cells that naturally migrate
into the physiologically intact vaginal mucosa before any priming
occurs in the DLN.
DC-dependent activation of naı¨ve T cells in vaginal tissue. To
completely isolate vaginal mucosa from all the other tissue
compartments, we developed a vaginal tissue culture system
(Fig. 6a). To detect the presence in the vaginal mucosa of APCs
that had taken up Ag after Ivag immunization and could prime
naı¨ve T cells, we Ivag immunized mice with SIINFEKL peptide
and resected the vaginal tissue at day 1 PI (Fig. 6a). The vaginal
tissue was digested in medium containing collagenase and DNase
followed by CD8 depletion to remove any endogenous CD8þ T
cells primed either within the vaginal mucosa or in the DLNs
followed by vaginal homing (Fig. 6a). We co-cultured the CD8-
depleted vaginal tissue together with CFSE-labelled naı¨ve OT-I
CD8þ T cells for 4 days without adding any Ag to the culture
(Fig. 6a) and tested Ag-speciﬁc CD8þ T-cell proliferation by
measuring CFSE dilution of the T cells cultured with the
immunized vaginal tissue compared with those cultured with
unimmunized vaginal tissue. Being co-cultured with the immu-
nized vaginal tissue, naı¨ve OT-I CD8þ T cells underwent sub-
stantial proliferation as compared with those co-cultured with
tissue from unimmunized mice (Fig. 6b,c). Moreover, if CD11cþ
cells (including DCs) were depleted from the immunized vaginal
tissue, the proliferation of OT-I CD8þ T cells was largely lost
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(Fig. 6b,c). Similarly, the cultures containing both immunized
vaginal tissue and naı¨ve OT-I CD8þ T cells showed signiﬁcantly
higher levels of IFN-g that was also dependent on the presence of
CD11cþ cells that had taken up Ag during Ivag immunization
(Fig. 6d). Therefore, the activation of naı¨ve CD8þ T cells in the
vaginal tissue required local vaginal APCs that were able to take
up Ag at the time of Ivag immunization and then present it later
to naı¨ve CD8þ T cells locally in the vaginal mucosa, without the
beneﬁt of LNs (not present in these vaginal tissue preparations).
Local expansion of Ag-speciﬁc CD8 T cells in vaginal mucosa.
We also asked whether the vaginal mucosa could support the
local expansion of Ag-speciﬁc CD8þ T cells. We characterized
the kinetics of CD8þ T-cell immune responses by measuring the
tetramer-positive CD8þ T cells at different time points after Ivag
immunization with rAd5-gp140 (Supplementary Fig. 5a). Day 7
was the earliest time point at which we could detect Ag-speciﬁc
CD8þ T cells in both the vaginal mucosa and the draining iliac
LNs (Supplementary Fig. 5b). We therefore decided to block
T-cell egress from LNs by FTY720 treatment starting from day 5
PI (Fig. 7a). The FTY720 treatment decreased blood Ag-speciﬁc
CD8þ T cells to a background level, similar to that in either naı¨ve
animals or the immunized animals sacriﬁced at day 5 PI (Fig. 7b).
In contrast, a similar amount of Ag-speciﬁc CD8þ T cells were
found in vaginal mucosa of FTY720-treated as untreated
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immunized mice (Fig. 7c). To determine whether the rAd5-gp140
Ivag immunization could induce the formation of IVALT similar
to that seen in rAd5-SIINFEKL immunized animals (Fig. 1d), we
examined vaginal tissue sections of immunized mice either with
or without FTY720 treatment by IHC (Fig. 7d). The formation of
IVALT containing CD3þ , CD8þ and CD11cþ cells was
observed in the immunized animals either treated or untreated
with FTY720. Because the FTY720 treatment diminished the
number of Ag-speciﬁc CD8þ T cells to a background level in the
bloodstream (Fig. 7b), which is the only pathway through which
the primed T cells can enter the vaginal mucosa from other tissue
compartments, we concluded that the quantity of vaginal Ag-
speciﬁc immune CD8þ T cells as well as the capability of IVALT
formation did not depend on blood replenishment.
To identify the proliferating Ag-speciﬁc CD8þ T cells within
the vaginal mucosa, we treated the immunized mice from day 5–9
with bromodeoxyuridine (BrdU), a synthetic thymidine analogue
that can be incorporated into newly synthesized DNA during cell
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proliferation (Fig. 8a). At day 10 PI, the amount of BrdUþ Ag-
speciﬁc CD8þ T cells in the vaginal mucosa was similar in both
FTY720-treated and -untreated immunized groups (Fig. 8b),
independent of trafﬁcking from LNs. In contrast, the FTY720
treatment caused a signiﬁcant increase of BrdUþ Ag-speciﬁc
CD8þ T cells in the iliac LNs due to blockage of T-cell egress
from DLNs (Fig. 8b). Thus, similar to what is found in the lung41,
the type-II vaginal mucosa can support Ag-speciﬁc CD8þ T-cell
local expansion that largely contributed to the quantity (the
absolute number of Ag-speciﬁc CD8þ T cells) and the quality
(the formation of IVALT) of vaginal Ag-speciﬁc CD8þ
T immunity, independent of systemic T-cell recruitment.
Discussion
In the present study, our results demonstrated for the ﬁrst time
that the vaginal mucosa can support the Ag-speciﬁc immune
priming of naı¨ve T cells and promote Ag-speciﬁc T-cell local
expansion, despite the absence of MALT or secondary lymphoid
tissues. Therefore, in addition to the known role of DLNs, the
type-II vaginal mucosa can also act as an inductive site for the
generation of primary CD8þ T-cell mucosal immune responses
independent of the DLNs, contrary to accepted belief.
The priming of immune responses in type-II mucosa is
thought to occur only in secondary lymphoid tissues, such as
DLNs where the APC-primed naı¨ve T cells can become memory
T cells and trafﬁc back to the mucosal sites. However, in direct
contrast to this existing widely believed paradigm, we have shown
vaginal Ag-speciﬁc CD8þ T-cell immune responses are possible
following primary Ivag vaccination in mice lacking DLNs (Fig. 1).
In agreement with our ﬁnding is a recent study by Roth et al.13
who reported the induction of HSV-speciﬁc immune responses in
the vagina of LN-deﬁcient LTaKO mice. Further, the priming of
CD8þ T cells in the absence of LN involvement has been
reported in the lungs (in type I mucosa)1–3 and other non-
lymphoid organs, such as the liver30,31. Indeed, in our study, we
also show the induction of CD8þ T-cell priming in the liver
(Fig. 3g,h). Moyron-Quiroz et al.1,2 showed that the induction of
CD8þ T cells in the lungs without LN involvement may occur in
induced bronchial-associated lymphoid tissues in type I mucosa.
Likewise, in this study, we demonstrate by IHC the formation of
IVALT in the vaginal mucosa following primary IVag
vaccination. Similar induction of IVALT has been reported in
hormone treated, TK HSV-vaccinated mice that are challenged
with WT HSV15. Despite previous studies showing immune
protection in the mice without LNs1–3,13 and the presence of
IVALT15, none of those studies were able to deﬁnitively
demonstrate the primary immune inductive site because they
did not exclude the possibilities that the immune priming can
occur in other non-lymphoid organs, such as liver and trafﬁc to
the vagina. By using the dual-transfer model to exclude trafﬁcking
from these or any other sites through the bloodstream, we have
now been able to deﬁnitively demonstrate that the vaginal type-II
mucosa acts as an inductive site for primary CD8þ T-cell
immunity. Therefore, our results demonstrated a new paradigm
of IVALT-associated local primary immune induction in type-II
mucosa (that lacks structured lymphoid tissues), which is totally
independent of any structured lymphoid and/or even non-
lymphoid tissues outside vaginal mucosa.
These results also demonstrate the ability to induce local
vaginal immunity more rapidly than could occur if time were
required for DCs to carry Ag to the DLNs and then for T cells to
migrate back through the blood to the mucosa. As we have seen
in the dual-transfer studies, the latter pathway requires additional
time (Fig. 3e versus Fig. 4d). This was conﬁrmed in the kinetic
study in unmanipulated mice (Fig. 5a,b). This kinetic difference
has important implications for vaccine delivery strategies aimed
at acute protective immunity.
Since the number of endogenous naı¨ve T cells speciﬁc to any
one peptide–major histocompatibility complex complex is
extremely small (20–200 per mouse)42, it is almost impossible
to detect a reliable population of Ag-speciﬁc T cells before clonal
expansion, after which the Ag-speciﬁc T cells are not naı¨ve
anymore. To test our hypothesis, we characterized vaginal local
immune priming of naı¨ve CD8þ T cells by the Ag-speciﬁc
activation of CD44-depleted Rag / OT-1 CD8þ T cells43
isolated from the spleen of naı¨ve animals (Fig. 3a), because OT-1
or similar TCR transgenic T cells are the only source of naı¨ve
CD8þ T cells of a homogeneous Ag speciﬁcity. The adoptively
transferred OT-1 CD8þ cells have been widely used and accepted
as naı¨ve Ag-speciﬁc T cells by many experienced labs, in which
the investigators published their studies using the transferred cells
from unimmunized transgenic mice as naı¨ve44–53, often even
without further puriﬁcation for CD62Lhigh and CD44low cells. In
the current study, we depleted all the CD62Llow and CD44high
cells right before the adoptive transfer and brought the purity of
our transferred naı¨ve CD8þ T cells up to 98.5% (Fig. 3a). Using
Day: 0 5 109
FTY720+BrdU Nx
Ivag:
rAd5-gp140
BrdU BrdU BrdU
FTY720
Imm.Naïve 
0
500
1,000
1,500
2,000
2,500
3,000
3,500
NS
0
5,000
10,000
15,000
20,000 Iliac LN
N
o.
 o
f B
rd
u+
 te
tra
m
er
+ 
CD
8 
T 
ce
lls
 p
er
 o
rg
an
Vaginal mucosa
P<0.01
P<0.001
P<0.001
P<0.01
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the dual-transfer model providing a large amount of naı¨ve T cells
at the local site, we could detect early immune priming at 24 h PI,
which is too short for the primed endogenous naı¨ve T cell to
reach a detectable level, most likely through clonal expansion.
The rapid detection of response by TCR transgenic T cells due to
the greater numbers of Ag-speciﬁc cells without an expansion
phase is therefore critical to carry out such studies, but does not
bear on their naı¨ve status.
We, like many other investigators studying vaginal mucosal
immunology12,13,15,21,22,26,54, treated all the experimental animals
with Depo-Provera, a long-acting progesterone, because vaginal Ag-
speciﬁc CD8þ T-cell immunity could not be consistently induced
in animals without Depo-Provera treatment. In contrast to humans,
the mouse passes through 4 oestrous stages during an oestrous cycle
that lasts only 4 days and then repeats: proestrus, oestrus, metestrus
and dioestrus55. Among the 4 stages, more CD8þ T cells have been
found present in vaginal mucosa during dioestrus56. Although the
detailed mechanisms of Depo-provera effects on vaginal mucosal
immunity remain to be clearly determined, the use of Depo-provera,
the dominant hormone in dioestrus, has been shown to affect the
thickness of vaginal epithelium22, the forming of IVALT15,54 and
the accumulation of CD11cþ cells22. We think the use of Depo-
provera, through the regulation of multiple immune parameters,
may make the vaginal mucosa more suitable to our Ivag
immunization. Without such synchronization of mice that
otherwise undergo rapid cyclic changes, it is impossible to carry
out controlled studies of vaginal immunity.
It is well accepted that T-cell-mediated local protective
immunity can play an important role to control the viral infection
in peripheral tissue compartments11,24–26. In addition to the
cytotoxic effects based on direct cell-to-cell contact, the tissue-
resident T memory cells (TRM) have been recently found to
undergo local development in skin57 and possess more protective
immune functions including the triggering of tissue-wide innate
and adaptive immune responses58,59. Therefore, a goal should be a
more efﬁcient vaccine strategy, which can generate strong local
T-cell-mediated immune responses60 without widespread systemic
immune activation that facilitates the replication of some viruses,
such as HIV and SIV61,62. Because the DLNs are not required to
induce vaginal immunity, it may be possible to induce local
immunity without systemic immune activation.
Our study outlines deﬁnitive evidence for the induction of
primary immune induction in vaginal type-II mucosa, thereby
identifying a new pathway of vaccine-induced mucosal immunity
and a new rationale for the design of future mucosal vaccine
strategies.
Methods
Mice. Because this was a study of vaginal immunity, all mice used in the current
study were females from 16–20 weeks of age. BALB/c and C57BL/6 mice were
purchased from NCI animal facility (Frederick, MD). OT-1, LTa KO and CXCR5
KO mice (all with C57BL/6 background) were purchased from Jackson Labora-
tories (Bar Harbor, ME). All experimental protocols were approved by and carried
out under the guidelines of the NCI’s Animal Care and Use Committee. All the
animals were grouped randomly and the number of animals in each group is equal
to or greater than 3 (nZ3). All the experiments were repeated at least two (two to
four) times.
Reagents and inocula. Replication-deﬁcient adenovirus 5-expressing HIVgp140
(rAd5-gp140) was developed and kindly provided by Dr Gary Nabel (Vaccine
Research Center, NIAID, Bethesda MD). Replication-deﬁcient adenovirus 5-
expressing SIINFEKL (rAd5-SIINFEKL) was ﬁrst developed by Dr S.E. Hensley in
Jon Yewdell’s and Jack Bennink’s laboratory (NIAID) and kindly provided by Dr
Robert Seder in (NIAID). The FTY720 was purchased from Cayman Chemical
(Ann Arbor, MI). The SIINFEKL peptide was purchased from Polypeptide
Laboratory (San Diego, CA). The mutant E. coli labile toxin (mLT) was a kind gift
of Dr John Clements (Tulane University, New Orleans). The DOTAP and BrdU
were purchased from Sigma (St Louis, MO). The Depo-provera was purchased
from the Department of Veterinary Medicine, NIH.
Intravascular T-cell staining. Alexa ﬂuor-647 labelled anti-mouse Thy1.2 anti-
body was diluted in PBS at 250 ngml 1. Each mouse was injected with 100 ml of
diluted antibody through the tail vein. All the animals were euthanized at 1min
post i.v. injection, a time point at which all the blood T cells in retro-orbital sinus
were Thy1.2 positive.
Dual transfer. The CD8þ T cells were isolated from Rag / OT-1 TCR
transgenic mice using a CD8 isolation kit (Miltenyi Biotec, Auburn, CA). The
CD44þ cells were depleted using biotinylated anti-mouse CD44 (1:2,000 dilution,
BioLegend, San Diego, CA) and anti-biotin beads (Miltenyi Biotec). The naı¨ve
CD8þ OT-1 T cells were labelled with either CFSE or violet dye (both from
Invitrogen, Grand Island, NY) at 5 mM. Ten microlitres of CFSE-labelled cells
(1 108ml 1) were directly injected into the vaginal tissue (Ivag) using a
Hamilton syringe with a 32G needle. One hundred microlitres of violet dye-labelled
cells (1 107ml 1) was injected into the tail vein (i.v.). The mice were under
isoﬂurane general anaesthesia during the performance of dual transfer.
Immunization. All the immunizations in this study were performed Ivag. The dose
of each inoculum was: 2 107 p.f.u. of rAd5-gp140, 1 107 of rAd5-SIINFEKL or
40 mg of SIINFEKL peptide plus 5 mg of mutant E. coli labile toxin (mLT) and equal
volume of DOTAP. Ivag immunizations were performed using a 20-ml pipette tip
to apply the inoculum into the vaginal canal atraumatically. All the immunized
mice were maintained under inhalation anaesthesia for 20min.
Vaginal tissue culture. The resected vaginal tissue was digested in RPMI 1640
medium (GIBCO, Grand Island, NY) containing collagenase-D (400Uml 1,
Roche Indianapolis, IN), DNase-I (2.5mgml 1, Roch), Penicillin–Streptomycin
(100 mgml 1, GIBCO), HEPES buffer (20mM, GIBCO) and fetal bovine serum
(10%, GIBCO). The digestion lasted for 20min with stirring. The vaginal tissue was
then smashed through a 70-mm cell strainer (Fisher, Pittsburgh, PA) followed by
CD8 depletion using Dynal Beads (Life Technologies). The CD8-depleted vaginal
tissue, either with or without CD11c-depletion (CD11c kit, Miltenyi Biotec), was
co-cultured with 1 106 CFSE (Invitrogen)-labelled naı¨ve OT-1 CD8þ T cells in
RPMI medium containing Penicillin–Streptomycin (100 mgml 1, GIBCO),
HEPES buffer (10mM, GIBCO), L-glutamine (2mM, GIBCO), gentamicin
(50mgml 1, Sigma), MEM non-essential amino acid (GIBCO), sodium pyruvate
(1mM, GIBCO), 2-mercaptoethanol (10 mM, Sigma), fungizone (2.5 mgml 1,
GIBCO) and fetal bovine serum (20%, GIBCO).
Antibodies and ﬂow cytometry. Anti-mouse CD3, CD8, CD69, CD44, CD25 and
CD62L were purchased from Biolegend and used to stain the cells at the con-
centration of 150 ngml 1. Data were collected using a LSRII using DIVA software
(BD Biosciences, San Jose, CA) or a FACSCalibur ﬂow cytometer using CellQuest
software (BD Biosciences). The analysis of data was performed using FlowJo (Tree
Star, Ashland, OR).
Depo-Provera synchronization. All the mice in our study received Depo-Provera
at a dose of 3mg per mouse through subcutaneous injection 5 days before each
experiment.
FTY720 treatments. FTY720 was given by IP injection at an initial dose of 50 mg
per mouse followed by daily maintenance injection at a dose of 5 mg per mouse.
Bromodeoxyuridine (BrdU) treatment and staining. The BrdU (1mg per
mouse, Sigma) was given by daily intraperitoneal injections for 5 days. The staining
of BrdU-positive cells was performed using a Brdu staining kit (BD Biosciences)
according to the manufacturer’s instructions.
Immunohistochemistry. The vagina was embedded in optimal cutting tempera-
ture compound (O.C.T.) and snap frozen in liquid nitrogen precooled isopentane.
Frozen vaginal tissue blocks were cut into sections with a thickness of 5 mm, stored
in  70 C until use. Cryostat sections were ﬁxed in acetone for 5min, rehydrated
in PBS and incubated overnight with primary antibodies including rabbit anti-
mouse CD3 (1:100 dilution, AbCam), rat anti-mouse CD8 (1:200 dilution, Biole-
gend) and hamster anti-mouse CD11c (1:150 dilution, Biolegend). The primary
antibodies were washed out three times by PBS followed by the addition of HRP-
conjugated secondary antibodies (Vector Lab) including horse anti-rabbit IgG, goat
anti-rat IgG and goat anti-hamster IgG. The secondary antibodies were incubated
in room temperature for 30min followed by DAB (kit from Vector Lab) devel-
opment and hematoxylin (BBC Biochemical) counter staining.
Statistics. The statistics of this study was performed using Prism software. One-
way analysis of variance plus Tukey’s multiple comparison was used to compare
multiple groups; Student’s t-test was used to compare two groups.
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